IDH1 and prostate carcinoma: Also in prostate cancers, tumor progression is led by an integrated signaling between androgen receptors (AR) and the extra-mitochondrial IDH1 activity, suggesting that targeted IDH1 therapies may be a possible therapeutic approach [154,155].